Millipore Sigma Expands cGMP Capacity
MilliporeSigma, the former Merck Millipore, has announced plans to expand its state-of-the-art single-use current good manufacturing process (cGMP) facility with the addition of the Mobius 2000L single-use bioreactor.
With the new upstream suite at its Biodevelopment Center in France, the company whose name reflects the takeover of US-based life sciences company Sigma Aldrich by Germany’s Merck KGaA, said it can now offer clients full process line cGMP manufacturing, comprised of MilliporeSigma's own instrumentation and products.
This, the company said, will allow it to advance clients' recombinant products from cell line development through to late-stage clinical production. At the point of tech transfer to a contract manufacturing organization or other facility, clients also will be able to leverage MilliporeSigma's Provantage End-to-End Services available worldwide to mitigate the risks traditionally associated with upscaling to commercial production.
“Our aim is to facilitate accelerated drug development and delivery via continued innovation and technical expertise by offering customers a complete end-to-end solution from clone to commercial production,” said Udit Batra, CEO of MilliporeSigma.
Provantage is a comprehensive suite of products and services that include process development, cGMP manufacturing, facility design, manufacturing equipment and consumables, process and equipment training, technology transfer and set-up for commercialization.
